Compare Nucor Corporation (NUE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Sana Biotechnology Inc — how do they compare? Nucor Corporation trades at $271.79 (market cap $61.93B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Nucor Corporation is far larger — about 54.8× Sana Biotechnology Inc's market cap, and Nucor Corporation pays a 0.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NUE | SANA | |
|---|---|---|
Market Cap | $61.93B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $5.92 |
52-Week Low | $131.78 | $2.68 |
Enterprise Value | $66.34B | $1.05B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $272.28, down 0.85% on the day, as the steel producer shows mixed technical signals with a bullish moving average trend but overbought RSI readings. Fundamentally, the company delivered strong Q2 2026 earnings beats with EPS of $4.84 versus $4.46 expected, while revenue trends show recovery from 2024 lows. Analyst sentiment remains positive with 59% buy ratings and a $279.63 consensus target, though recent tariff developments and cyclical steel demand create headwinds.
The outlook for NUE appears cautiously optimistic with improving earnings momentum and favorable analyst coverage, though investors face risks from steel price volatility and macroeconomic pressures. The stock's current valuation at 21.7x P/E appears reasonable given the earnings recovery trajectory, but requires sustained operational execution to justify further upside beyond current resistance levels near $275.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
